Current kinase inhibitors cover a tiny fraction of fragment space

doi:10.1016/j.bmcl.2015.04.005

Bioorganic & Medicinal Chemistry Letters

Volume 25, Issue 11, 1 June 2015, Pages 2372-2376

https://doi.org/10.1016/j.bmcl.2015.04.005 Get rights and content

Abstract

We analyze the chemical space coverage of kinase inhibitors in the public domain from a fragment point of view. A set of 26,668 kinase inhibitors from the ChEMBL database of bioactive molecules were decomposed automatically by fragmentation at rotatable bonds. Remarkably, about half of the resulting 10,302 fragments originate from inaccessible libraries, as they are not present in commercially available compounds. By mapping to the established kinase pharmacophore models, privileged fragments in sub-pockets are identified, for example, the 5681 ring-containing fragments capable of forming bi-dentate hydrogen bonds with the hinge region in the ATP binding site. Surprisingly, hinge-binding fragments in current kinase inhibitors cover only 1% of the potential hinge-binders obtained by decomposing a library of nearly 7.5 million commercially available compounds, which indicates that a large fraction of chemical space is unexplored.

Graphical abstract

References and notes (26)

J. Zhang et al.
Nat. Rev. Cancer
(2009)
H. Zhao et al.
Bioorg. Med. Chem. Lett.
(2014)
H. Zhao et al.
Eur. J. Med. Chem.
(2015)
O. Fedorov et al.
Chem. Biol.
(2011)
C.A. Lipinski et al.
Adv. Drug Deliv. Rev.
(2001)
T.J. Ritchie et al.
Drug Discovery Today
(2011)
Y. Liu et al.
Nat. Chem. Biol.
(2006)
F. Zuccotto et al.
J. Med. Chem.
(2010)
L.K. Gavrin et al.
Medchemcomm
(2013)
D.E. Scott et al.
Biochemistry
(2012)

H.T. Zhao et al.

ACS Med. Chem. Lett.

(2012)

P. Kolb et al.

Proteins

(2008)

K. Lafleur et al.

J. Med. Chem.

(2009)

Cited by (18)

A survey of applications of tetrahydropyrrolo-3,4-azoles and tetrahydropyrrolo-2,3-azoles in medicinal chemistry
2021, Advances in Heterocyclic Chemistry
Citation Excerpt :
Danusertib (81) is the prototype of the kinase inhibitor class originating from the Nerviano site of Pharamacia and emerging from an initiative to develop proprietary libraries based on core structural elements specifically designed to inhibit protein kinases by engaging the hinge residues in a fashion modeled on the interactions with ATP (Fig. 13).47,48 The design of the fused amino pyrazole in 81 was inspired by 3-aminopyrazole- and 3-aminoindazole-based hinge binders but with recognition of the unique and rigid nature of the bicyclic scaffold that offered vectors suitable for further decoration.41,49–51 An X-ray of a prototype compound PHA-533514 (82) bound to Aurora kinase A confirmed the anticipated binding mode and set the stage for further structural exploration.
Tetrahydropyrrolo-3,4-azoles and tetrahydropyrrolo-2,3-azoles represent an interesting family of heterocycles that offer potential utility in drug design as either scaffolds or pharmacophoric elements. The tetrahydropyrrolo[3,4-c]pyrazole ring system is the most explored representative of this class of heterobicycle which is represented in the marketed dipeptidyl peptidase-4 inhibitor omarigliptin and the Phase 2 clinical candidate danusertib, an Aurora kinase inhibitor. In this chapter, we provide an overview of the synthesis of tetrahydropyrrolo-3,4-azoles and summarize their applications in drug design and discovery. In contrast, the tetrahydropyrrolo-2,3-azole series has been only sparsely explored with no significant systematic study or defined application in drug design.
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
2021, European Journal of Medicinal Chemistry
Citation Excerpt :
HERs’ overexpression in tumor cell lines is regarded as a negative poor sign. FDA has approved more than thirty kinase inhibitors [107,108], of which, inhibitors of receptor tyrosine kinase (RTKs) have significant therapeutic effects in the combat against different cancers. FDA has approved several RTK inhibitors, and many others are in different clinical trials phases.
Despite the encouraging clinical progress of chemotherapeutic agents in cancer treatment, innovation and development of new effective anticancer candidates still represents a challenging endeavor. With 15 million death every year in 2030 according to the estimates, cancer has increased rising of an alarm as a real crisis for public health and health systems worldwide. Therefore, scientist began to introduce innovative solutions to control the cancer global health problem. One of the promising strategies in this issue is the multitarget or smart hybrids having two or more pharmacophores targeting cancer. These rationalized hybrid molecules have gained great interests in cancer treatment as they are capable to simultaneously inhibit more than cancer pathway or target without drug-drug interactions and with less side effects. A prime important example of these hybrids, the HDAC hybrid inhibitors or referred as multitargeting HDAC inhibitors. The ability of HDAC inhibitors to synergistically improve the efficacy of other anti-cancer drugs and moreover, the ease of HDAC inhibitors cap group modification prompt many medicinal chemists to innovate and develop new generation of HDAC hybrid inhibitors. Notably, and during this short period, there are four HDAC inhibitor hybrids have entered different phases of clinical trials for treatment of different types of blood and solid tumors, namely; CUDC-101, CUDC-907, Tinostamustine, and Domatinostat. This review shed light on the most recent hybrids of HDACIs with one or more other cancer target pharmacophore. The designed multitarget hybrids include topoisomerase inhibitors, kinase inhibitors, nitric oxide releasers, antiandrogens, FLT3 and JAC-2 inhibitors, PDE5-inhibitors, NAMPT-inhibitors, Protease inhibitors, BRD4-inhibitors and other targets. This review may help researchers in development and discovery of new horizons in cancer treatment.
Privileged Structures and Motifs (Synthetic and Natural Scaffolds)
2017, Comprehensive Medicinal Chemistry III
In the constantly evolving world of drug discovery, there remains a constant: the privileged structure. In this article, we define and review the concept of the privileged structure. We focus on its applications and limitations, reviewing the main classes and introducing an updated clustering system based on the most commonly encountered structural features. Sources of these privileged scaffolds both synthetic and natural are exemplified. Finally, we look at “lead-like” synthesis and its future in privileged drug discovery.
Identification of azepinone fused tetracyclic heterocycles as new chemotypes with protein kinase inhibitory activities
2016, Tetrahedron
Citation Excerpt :
Structural modifications of the paullone basic scaffold switched the selectivity profile leading to dual polo-like kinase 1 (PLK1)/vascular endothelial growth factor-receptor 2 (VEGF-R2) inhibitors with in vitro antiproliferative and antiangiogenetic activities.8 Furthermore, congener derivatives have been described with interesting sirtuin 1 (SIRT1) modulatory,9 antitrypanosomal10 and antileishmanial activity.11 Hymenialdisine (2), a pyrroloazepinone natural product, has shown potent inhibitory activity against CDKs, GSK-3β, casein kinase 1 (CK1) and checkpoint kinase (Chk) 1 and 2,12 as well as anti-inflammatory,13 neuroprotective and antioxidant properties.14
The design and synthesis of small tetracyclic heterocycles which bear two new regioisomeric 2-carboxyethyl-1H-pyrrole-annulated indoloazepinone scaffolds is described. An azepinone motif, which is inherent in the structures of many well studied protein kinase inhibitors, serves as prominent structural feature of the new compounds. Concise access to the new regioisomeric tetracyclic derivatives was accomplished through amide coupling of appropriate pyrrole and indole precursors followed by an intramolecular Heck coupling reaction of the intermediate amide conjugates. Preliminary evaluation of newly synthesized tetracyclic molecules against a panel of protein kinases indicated their inhibitory activities and revealed promising selectivity profiles. The new compounds displayed no significant antiproliferative activity against MCF-7 cancer cells. Interestingly, derivative 19a exhibited selective TAK1 kinase inhibitory activity and figures as a promising chemotype for the discovery of new TAK1 inhibitors.
Enriching screening libraries with bioactive fragment space
2016, Bioorganic and Medicinal Chemistry Letters
By deconvoluting 238,073 bioactive molecules in the ChEMBL library into extended Murcko ring systems, we identified a set of 2245 ring systems present in at least 10 molecules. These ring systems belong to 2221 clusters by ECFP4 fingerprints with a minimum intracluster similarity of 0.8. Their overlap with ring systems in commercial libraries was further quantified. Our findings suggest that success of a small fragment library is driven by the convergence of effective coverage of bioactive ring systems (e.g., 10% coverage by 1000 fragments vs. 40% by 2 million HTS compounds), high enrichment of bioactive ring systems, and low molecular complexity enhancing the probability of a match with the protein targets. Reconciling with the previous studies, bioactive ring systems are underrepresented in screening libraries. As such, we propose a library of virtual fragments with key functionalities via fragmentation of bioactive molecules. Its utility is exemplified by a prospective application on protein kinase CK2, resulting in the discovery of a series of novel inhibitors with the most potent compound having an IC₅₀ of 0.5 μM and a ligand efficiency of 0.41 kcal/mol per heavy atom.
Kinase hinge binding scaffolds and their hydrogen bond patterns
2015, Bioorganic and Medicinal Chemistry
Citation Excerpt :
In order to make better decisions to select, design and prioritize multiple chemotypes of choice for lead optimization, understanding the interaction patterns of the primary scaffolds that anchor the compounds via hinge hydrogen bonds is of paramount importance. Recently putative hinge-binding fragments were compiled from decomposing known kinase inhibitors mapping to kinase pharmacophore models.18 We have previously reported the extraction of kinase hinge binding scaffolds from large body of X-ray structural data.19
Protein kinases constitute a major class of intracellular signaling molecules, and describe some of the most prominent drug targets. Kinase inhibitors commonly employ small chemical scaffolds that form hydrogen bonds with the kinase hinge residues connecting the N- and C-terminal lobes of the catalytic domain. In general the satisfied hydrogen bonds are required for potent inhibition, therefore constituting a conserved feature in the majority of inhibitor-kinase interactions. From systematically analyzing the kinase scaffolds extracted from Pfizer crystal structure database (CSDb) we recognize that large number of kinase inhibitors of diverse chemical structures are derived from a relatively small number of common scaffolds. Depending on specific substitution patterns, scaffolds may demonstrate versatile binding capacities to interact with kinase hinge. Afforded by thousands of ligand–protein binary complexes, the hinge hydrogen bond patterns were analyzed with a focus on their three-dimensional configurations. Most of the compounds engage H6 NH for hinge recognition. Dual hydrogen bonds are commonly observed with additional recruitment of H4 CO upstream and/or H6 CO downstream. Triple hydrogen bonds accounts for small number of binary complexes. An unusual hydrogen bond with a non-canonical H5 conformation is observed, requiring a peptide bond flip by a glycine residue at the H6 position. Additional hydrogen bonds to kinase hinge do not necessarily correlate with an increase in potency; conversely they appear to compromise kinase selectivity. Such learnings could enhance the prospect of successful therapy design.

View all citing articles on Scopus

View full text

Current kinase inhibitors cover a tiny fraction of fragment space

Abstract

Graphical abstract

Nat. Rev. Cancer

Bioorg. Med. Chem. Lett.

Eur. J. Med. Chem.

Chem. Biol.

Adv. Drug Deliv. Rev.

Drug Discovery Today

Nat. Chem. Biol.

J. Med. Chem.

Medchemcomm

Biochemistry

ACS Med. Chem. Lett.

Proteins

J. Med. Chem.